Latest Articlesddd
AstraZeneca and Merck PARP Inhibitor Lynparza The AstraZeneca (AZN) and Merck (MRK) PARP inhibitor Lynparza (olaparib) has …
Pfizer to Acquire Array Pfizer (PFE) announced that it has agreed to acquire Array Biopharma (ARRY) …
Why has bluebird bio Been Hammered in the Market Recently? Investors should be asking why bluebird …
Nektar Announced Results for NKTR-358 During an oral session at the Annual European Congress of Rheumatology …
Good News about Novartis’ Cosentyx® for Psoriatic Arthritis Novartis (NVS) has good news for Cosentyx®. Data emerging out …
Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed …
Vertex and CRISPR Therapeutics While some groups are doubting the gene editing capability of CRISPR gene …
AT ASCO Gilead Sciences and Yescarta® By Acquiring Kite Pharma Gilead Sciences(GILD) gained Kite’s CAR T technology …
Zynteglo™ from bluebird bio Gets European Conditional Approval European marketing authorization for Zynteglo follows the fastest …
What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is …
Positive Results from Korsuva for Pruritis Cara Therapeutics Postive Results from Korsuva Trial On May 29, …
Incyte's FDA Approval Based on encouraging data from the REACH1 trial the FDA approved a label …
Prohost Letter #431 Genomes, Genes and Gene Therapies In this issue of the Prohost Letter we …
Amgen, the Biotech King Amgen (AMGN), the biotech king, wanted to buy all of the Denmark …
Vertex’s Good News Vertex and Kymera Therapeutics Collaboration Last week Vertex Pharmaceuticals (VRTX) and Kymera Therapeutics entered …
Great News for Array BioPharma Array BioPharma (ARRY) announced positive results from the interim analysis of …
The Medicines Company Are Inclisiran's Clinical Trial Results Impressive? Our answer is YES. The trial results …
About Iovance Biotherapeutics Iovance Biotherapeutics (IOVA) is a late-stage biotechnology company developing novel cancer immunotherapies based on …
Advaxis Outperformed on a Negative Market Day ADXS Outperformed Advaxis’ (ADXS) stock rallied today as the …
The FDA Approval of Regeneron's EYLEA Is Important The PANORAMA Trial of EYLEA for Diabetic Retinopathy …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
